-- System to debut at 41st Annual DIA Mtg, Washington DC, June 26-29, Booth 1457
EMERYVILLE CA USA -- JUNE 16 2005 -- Sierra Scientific Software, a leading provider of integrated clinical research software solutions, announced the debut today of its leading-edge eClinical Trial Solution, which is capable of supporting all of the clinical research at the largest institutions.
IMPLEMENTATION OF CRIS PROVIDES INSTITUTIONS:
SUPPORTS UNLIMITED NUMBER OF TRIALS, ANY SIZE:
David Thomas, Sierra's CEO, states, "Culminating 10 years of development, 8 versions and rigorous use by industry, with CRIS v8 we have created a complete information management system for eClinical Trials." (The specification sheet is below:)
http://sacserv.com/links.jsp?linkid=20909&subid=686369&custid=76&campid=142247&type=0
"CRIS supports an unlimited number of trials of any size, and with the customer support provided by our partner, SAIC, 24/7 global help-desk and robust hosting services make it easy to implement. With CRIS, the institution can connect all participants in the trial process, from investigators, clinical data centers, IRBs and sponsors. With CRIS, every investigator has access to state-of-the-art technology, capital and training costs are reduced and all stakeholders are integrated into the trial process. We are confident that CRIS provides institutions with an outstanding value proposition and will be pleased to show you why," says Thomas.
CRISv8 is the result of a joint development program through the strategic alliance between Sierra Scientific Software, Inc. (Sierra) and Science Applications International Corp (SAIC). CRIS is developed within SAIC's stringent development processes, procedures, and supported by SAIC's world-class hosting, 24/7 help desk and implementation service capabilities; as used by the largest entities, such as Bristol Myers Squibb and the National Cancer Institute.
The SAIC/Sierra Alliance provides comprehensive service and support functions to implement CRIS in-house, as a hosted service, or accessed on an ASP basis. Services are available from SAIC's ISO 9001:2000-certified North American Integrated Services Management Center (NAISMC). These services include customization, integration, validation, data migration and user training. A global 24/7 Help Desk, in languages as required, is also available. For additional information regarding SAIC's capabilities, access the brochure, Pharmaceutical/Biotechnology IT Challenges:
http://sacserv.com/links.jsp?linkid=20910&subid=686369&custid=76&campid=142247&type=0
"Using CRISv8 means institutions and their investigator's have at their fingertips the tools to execute world-class clinical research," Thomas concludes.
DIA EXHIBITION:
Come see Sierra, SAIC and CRIS v8 at the 41st Annual DIA meeting in Washington DC, on June 26-29 2005, at Booth 1457.
Visit the websites below to learn more about the companies' combined capabilities:
http://sacserv.com/links.jsp?linkid=20911&subid=686369&custid=76&campid=142247&type=0
http://sacserv.com/links.jsp?linkid=20912&subid=686369&custid=76&campid=142247&type=0
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.